Anti-LAG3 antibody (Gloria) |
|
Phase 1 Clinical |
Harbin Gloria Pharmaceuticals Co Ltd |
Solid tumours; Neoplasms |
Details
|
KL-A289 |
KL-A289 |
Phase 1 Clinical |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, Anyuan Pharmaceutical Technology (Shanghai) Co Ltd |
Solid tumours |
Details
|
MIL-98 |
MIL-98 |
Phase 1 Clinical |
Beijing Mabworks Biotech Co Ltd |
Solid tumours; Breast Neoplasms; Lymphoma; Melanoma |
Details
|
Mavezelimab |
MK-4280 |
Phase 2 Clinical |
Merck Sharp & Dohme Corp |
Lymphoma, B-Cell; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung |
Details
|
Bavunalimab |
XmAb-22841; XmAb-841 |
Phase 1 Clinical |
Xencor Inc |
Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Solid tumours; Cholangiocarcinoma; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck |
Details
|
ABL-501 |
ABL-501 |
Phase 1 Clinical |
Abl Bio Inc |
Solid tumours |
Details
|
Encelimab |
TSR-033; TSR 033; TSR033; GSK-4074386 |
Phase 1 Clinical |
Anaptysbio Inc |
Neoplasms |
Details
|
IBI-323(Innovent Biologics) |
IBI-323 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
EMB-02 |
EMB-02 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Solid tumours; Neoplasms |
Details
|
FS 118 |
FS-118 |
Phase 2 Clinical |
Merck Serono, F-Star |
Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neoplasm Metastasis |
Details
|
SHR-1802 |
SHR-1802 |
Phase 2 Clinical |
Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
Tebotelimab |
PD-1 X LAG-3; MGD-013 |
Phase 3 Clinical |
Macrogenics Inc |
Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Cholangiocarcinoma; Small Cell Lung Carcinoma; Liver Neoplasms; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Biliary Tract Neoplasms; Ovarian Neoplasms; Hematologic Neoplasms; Head and Neck Neoplasms; Solid tumours |
Details
|
DNV-3 |
DNV3; DNV-3 |
Phase 2 Clinical |
Zhejiang Shimai Pharmaceutical Co Ltd |
Solid tumours; Skin Neoplasms; Neoplasms; Lymphoma |
Details
|
AK-129 |
AK-129 |
Phase 1 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Neoplasms |
Details
|
RO-7247669 |
RO-7247669 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Liver Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
INCAGN-2385 |
INCAGN-2385; INCAGN-02385 |
Phase 2 Clinical |
Agenus Inc, Incyte Corp |
Head and Neck Neoplasms; Melanoma |
Details
|
IBI-110 |
IBI-110 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
HLX-26 |
HLX-26 |
Phase 2 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours; Colorectal Neoplasms; Lymphoma |
Details
|
Mavezelimab/Pembrolizumab |
MK-4280A; MK-4820A |
Phase 3 Clinical |
Msd Ireland (Carlow) Merck Sharp & Dohme Corp, Moshadong R & D (China) Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Small Cell Lung Carcinoma; Colorectal Neoplasms |
Details
|
Miptenalimab |
BI-754111 |
Phase 2 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Head and Neck Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
Relatlimab |
ONO-4482; BMS-986016 |
Phase 3 Clinical |
Bristol-Myers Squibb Company |
Chordoma; Adenocarcinoma; Carcinoma, Hepatocellular; Large intestine neoplasm; Melanoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gliosarcoma; Colorectal Neoplasms; Brain Neoplasms; Sarcoma; Hematologic Neoplasms; Uveal melanoma; Microsatellite instability-high cancer; Multiple Myeloma; Glioblastoma; Hodgkin Disease; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Solid tumours |
Details
|
Fianlimab |
REGN-3767 |
Phase 3 Clinical |
Regeneron Pharmaceuticals Inc |
Melanoma |
Details
|
INCA-32459 |
INCA-32459 |
Phase 1 Clinical |
Incyte Corp, Merus Nv |
Neoplasms |
Details
|
LBL-007 |
LBL-007 |
Phase 2 Clinical |
Leads Biolabs Inc, Nanjing Leads Biolabs Co Ltd |
Solid tumours; Neoplasms; Colorectal Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Sym-022 |
Sym-022 |
Phase 1 Clinical |
Symphogen A/S |
Solid tumours; Lymphoma; Neoplasm Metastasis |
Details
|
Ieramilimab |
IMP-701; LAG-525 |
Phase 2 Clinical |
Immutep |
Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Esophageal adenocarcinoma; Persistent Fetal Circulation Syndrome; Melanoma |
Details
|
Eftilagimod alpha |
hLAG-3Ig; CD-223; EDP-202; EOC-202; IMP-321 |
Phase 2 Clinical |
Immutep, Prima Biomed Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma |
Details
|